Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)

There is a significant interest in designing therapeutic agents that can enhance ADCC and thereby improve clinical responses with approved antibodies. We recently reported the combination of an imidazoquinoline-based TLR7/8 agonist (522) with a monoclonal antibody improved ADCC in vitro and in vivo....

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Vidhi, Kim, Hyunjoon, Zhang, Wenqiu, Larson, Peter, Shah, Manan, Griffith, Thomas S., Ferguson, David, Panyam, Jayanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870826/
https://www.ncbi.nlm.nih.gov/pubmed/33558639
http://dx.doi.org/10.1038/s41598-021-83005-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870826/
https://www.ncbi.nlm.nih.gov/pubmed/33558639
http://dx.doi.org/10.1038/s41598-021-83005-6

Ejemplares similares